Boosting resting natural killer (NK) cells to better attack harmful cells
Non-Activated Natural Killer Cell Engineering For Enhanced Cytotoxic Potential
['FUNDING_SBIR_2'] · KYTOPEN CORP · NIH-11164690
The team is modifying resting natural killer (NK) immune cells using a non-viral method so they become better at finding and killing cancer cells and cells involved in autoimmune disease.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | KYTOPEN CORP (nih funded) |
| Locations | 1 site (CAMBRIDGE, UNITED STATES) |
| Trial ID | NIH-11164690 on ClinicalTrials.gov |
What this research studies
You should know this is early-stage lab research that uses a novel electric-field delivery system (Flowfect™) to put gene-editing tools into non-activated human NK cells without using viruses. Researchers will first optimize conditions so the cells survive and keep their normal functions after editing. They will create stable gene knockouts in NK cells and test the edited cells in lab dishes and animal models to understand safety and activity. The work is meant to support later preclinical development of NK-based therapies for cancers and autoimmune conditions.
Who could benefit from this research
Good fit: Future candidates would most likely include people with blood cancers such as acute myeloid leukemia or patients with autoimmune conditions where NK cell-based approaches might help.
Not a fit: People with conditions unrelated to NK cell function or those needing immediate standard care are unlikely to benefit directly from this early preclinical work.
Why it matters
Potential benefit: If successful, this could enable safer, more reliable NK cell therapies that better control cancers and certain autoimmune diseases by allowing precise non-viral gene edits.
How similar studies have performed: Other NK-cell engineering and CAR‑NK approaches using viral methods have shown early clinical promise, but efficient non-viral gene editing of resting NK cells remains relatively new.
Where this research is happening
CAMBRIDGE, UNITED STATES
- KYTOPEN CORP — CAMBRIDGE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: CHIU, MICHAEL — KYTOPEN CORP
- Study coordinator: CHIU, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Autoimmune Diseases